1. Resource table {#s0005}
=================

Name of stem cell lineKCL038InstitutionKing\'s College London, London UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: dusko.ilic\@kcl.ac.ukDate archived/stock dateDec 06, 2011Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D., 2013. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol. Med. 5 (1), 10-17.doi: 10.1002/emmm.201201973 [[http://www.ncbi.nlm.nih.gov/pubmed/23161805]{.ul}](http://www.ncbi.nlm.nih.gov/pubmed/23161805){#ir0005}\
2)Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P., Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J., Moore, H.D., Murray, H., Kunath, T., 2015. The molecular karyotype of 25 clinical-grade human embryonic stem cells lines. *Sci. Rep.* 5, 17258.doi: 10.1038/srep17258 http://www.ncbi.nlm.nih.gov/pubmed/26607962\
3)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122-128.doi: 10.3109/14653249.2011.623692\
[[http://www.ncbi.nlm.nih.gov/pubmed/22029654]{.ul}](http://www.ncbi.nlm.nih.gov/pubmed/22029654){#ir0010}\
4)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366-1381.doi: 10.1038/nprot.2012.080\
[[http://www.ncbi.nlm.nih.gov/pubmed/22722371]{.ul}](http://www.ncbi.nlm.nih.gov/pubmed/22722371){#ir0015}Information in public databasesKCL038 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: NIHhESC-14-0265\
http://grants.nih.gov/stem_cells/registry/current.htm?id = 674EthicsThe hESC line KCL038 is derived under license from the UK Human Fertilisation and Embryology Authority (research licence numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

2. Resource details {#s0010}
===================

Consent signedJan 12, 2010Embryo thawedOct 24, 2011UK Stem Cell Bank Deposit ApprovalReference: SCSC12-37SexMale 46, XYGradeClinicalDisease statusHealthy/UnaffectedKaryotype (aCGH)Deletion of approximately 683 kb from band in the long arm of chromosome 5q13.2. The deletion represents benign copy number variant.SNP ArrayNo abnormalities detected [@bb0005]DNA fingerprintAllele sizes (in bp) of 16 microsatellite markers specific for chromosomes 13, 18 and 21 [@bb0025]HLA typingHLA-A 03,11; B 07,15; Bw 06; C 03,07; DRB1 14,15; DRB3 02; DQB1 05,06 [@bb0025], [@bb0005]Viability testingPassMycoplasmaNegativeSterilityPassPluripotent markers\
(immunostaining)\
([Fig. 1](#f0005){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityThree germ layers differentiation in vitro\
(immunostaining)\
([Fig. 2](#f0010){ref-type="fig"})Endoderm: AFP\
Ectoderm: TUBB3 (tubulin, beta 3 class III)\
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)Sibling lines availableNo

We generated KCL038 clinical grade hESC line following protocols, established previously ([@bb0020], [@bb0030]), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after freeze/thaw cycle ([Fig. 1](#f0005){ref-type="fig"}). Differentiation potential into three germ layers was verified in vitro ([Fig. 2](#f0010){ref-type="fig"}).

Molecular karyotyping identified deletion of approximately 683 kb from band q13.2 in the long arm of chromosome 5 (69,705,561 -- 70,388,844). The deletion represents benign copy number variant.

The KCL038 line is confirmed by PCR to be negative for Human Immunodeficiency Virus 1 (HIV1), and Hepatitis C Virus (HepC, HCV). We did not retest the line.

We also generated research grade of KCL038 line that is adapted to feeder-free conditions.

3. Materials and methods {#s0015}
========================

3.1. Consenting process {#s0020}
-----------------------

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.6) were created on Dec 18, 2008. HFEA Code of Practice that was in effect at the time of document creation: Edition 7 -- R.4 ([[http://www.hfea.gov.uk/2999.html]{.ul}](http://www.hfea.gov.uk/2999.html){#ir0020}). The donor couple signed the consent on Jan 12, 2010. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8---R.1. HFEA Code of Practice Edition 7---R.4 was in effect: 02 Oct 2008--30 Sep 2009, whereas 8---R.1 was in effect: 01 Oct 2009--06 Apr 2010.

3.2. Embryo culture and micromanipulation {#s0025}
-----------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0020], [@bb0030]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

3.3. Cell culture {#s0030}
-----------------

ICM plated on mitotically inactivated HFF were cultured as described ([@bb0020], [@bb0030]). TE cells were removed mechanically from outgrowth ([@bb0010], [@bb0015]). hES colonies were expanded and cryopreserved at the third passage.

3.4. Viability test {#s0035}
-------------------

Straws with the earliest frozen passage (p.2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

3.5. Pluripotency markers {#s0040}
-------------------------

Pluripotency was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as described ([@bb0020], [@bb0030]).

3.6. Genotyping {#s0045}
---------------

DNA was extracted from hES cell cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as described ([@bb0020]). Allele sizes were recorded to give a unique fingerprint of each cell line.

3.7. Array comparative genomic hybridization (aCGH) {#s0050}
---------------------------------------------------

aCGH was performed as described in details ([@bb0020]).

3.8. SNP array {#s0055}
--------------

SNP array was performed as described in details ([@bb0005]).

3.9. HLA typing {#s0060}
---------------

HLA-A, -B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy\'s and St Thomas\' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy\'s Hospital, London, UK) as described ([@bb0025]).
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![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.](gr1){#f0005}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (red) for mesoderm, β-III tubulin (red) for ectoderm and α-fetoprotein (red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.](gr2){#f0010}
